Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

A new systematic review and meta-analysis published in the Clinical Nutrition ESPEN revealed promising outcomes for the ...

Investors are upset at a lack of clarity over the results of Wegovy successor CagriSema after trials published in December.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Wegovy is a GLP-1 agonist containing semaglutide ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.